1.Recalcitrant gram-positive bacterial keratitis treated with intrastromal levofloxacin 1.5% ophthalmic solution: A case report and review of literature
Bobbie Marie M. Santos ; Josept Mari S. Poblete ; George Michael N. Sosuan ; Pablito F. Sandoval Jr. ; Billie Jean T. Cordero ; David Ammiel R. Tirol V ; Ruben Lim Bon Siong
Philippine Journal of Ophthalmology 2024;49(1):54-60
Objective:
This paper demonstrated the effectiveness of intrastromal injection of levofloxacin 1.5%
ophthalmic solution in the management of recalcitrant Gram-positive bacterial keratitis.
Methods:
This is a report on two cases of recalcitrant bacterial keratitis encountered at the External Diseases
and Cornea Clinic of the Department of Ophthalmology and Visual Sciences at the Philippine General Hospital.
Results:
Two middle-aged females presented with bacterial keratitis unresponsive to previous antibiotic
treatment with impending corneal perforation. The Gram stain of the corneal scraping in the first case revealed Gram-positive cocci, while the second case showed encapsulated Gram-positive bacilli and encapsulated Grampositive cocci in chains. In both cases, repeated intrastromal injections of levofloxacin 1.5% in addition to increasing the frequency of topical levofloxacin 1.5% resulted in marked improvement in visual acuity and resolution of deep stromal infiltrates and hypopyon.
Conclusion
These cases highlighted the utility of intrastromal levofloxacin 1.5% ophthalmic solution in the
management of recalcitrant Gram-positive bacterial keratitis.
Fluoroquinolones
;
Levofloxacin
2.Clinical and etiological characteristics of infectious vulvovaginitis in children in Zhejiang province from 2009 to 2019.
Hui Hui GAO ; Sun Yi WANG ; Yu Chen ZHANG ; Ming Ming ZHOU ; Chun Zhen HUA ; Chang Zheng YUAN ; Li Ying SUN
Chinese Journal of Pediatrics 2023;61(11):1024-1030
Objective: To explore the clinical characteristics, common pathogens in children with vulvovaginitis. Methods: This was a retrospective cases study. A total of 3 268 children with vulvovaginitis were enrolled, who visited the Department of Pediatric and Adolescent Gynecology, Children's Hospital, Zhejiang University School of Medicine from January 2009 to December 2019. Patients were divided into 3 groups according to the age of <7, 7-<10 and 10-18 years. Patients were also divided in to 4 groups according to the season of first visit. The pathogen distribution characteristics of infective vulvovaginitis were compared between the groups. Their clinical data were collected and then analyzed by χ2 test. Results: The were 3 268 girls aged (6.2±2.5) years. There were 1 728 cases (52.9%) aged <7 years, 875 cases (26.8%) aged 7-<10 years, and 665 cases (20.3%) aged 10-18 years. Of these cases, 2 253 cases (68.9%) were bacterial vulvovaginitis, 715 cases (21.9%) were fungal vulvovaginitis and 300 cases (9.2%) were vulvovaginitis infected with other pathogens. Bacterial culture of vaginal secretions was performed in 2 287 cases, and 2 287 strains (70.0%) of pathogens were detected, of which the top 5 pathogens were Streptococcus pyogenes (745 strains, 32.6%), Haemophilus influenzae (717 strains, 31.4%), Escherichia coli (292 strains, 12.8%), Staphylococcus aureus (222 strains, 9.7%) and Klebsiella pneumoniae (67 strains, 2.9%). Regarding different age groups, H.influenzae was the most common in children under 7 years of age (40.3%, 509/1 263), S.pyogenes (41.9%, 356/849) was predominantly in children aged 7 to 10 years, and E.coli was predominant in children aged 10 to 18 years (26.3%, 46/175). Susceptibility results showed that S.pyogenes was susceptible to penicillin G (610/610, 100.0%), ceftriaxone (525/525, 100.0%), and vancomycin (610/610, 100.0%); the resistance rates to erythromycin and clindamycin were 91.9% (501/545)and 90.7% (495/546), respectively. For H.influenzae, 32.5% (161/496) produced β-elactamase, and all strains were sensitive to meropenem (489/489, 100.0%) and levofloxacin (388/388, 100.0%), while 40.5% (202/499) were resistant to ampicillin. Among E.coli, all strains were sensitive to imipenem(100%, 175/175). The resistance rates of E.coli to levofloxacin and ceftriaxone were 29.1% (43/148) and 35.1% (59/168), respectively. A total of 48 strains of methicillin-resistant Staphylococcus aureus (MRSA) were isolated with a proportion of 28.3% (45/159) in 3 268 patients. The results of drug susceptibility test showed that all MRSA strains were sensitive to linezolid 100.0% (40/40), vancomycin (45/45, 100.0%), and tigecycline (36/36, 100.0%); the resistance rates of MRSA to penicillin G, erythromycin and clindamycin were 100% (45/45), 95.6% (43/45) and 88.9% (40/45), respectively. All methicillin-sensitive Staphylococcus aureus (MSSA) strains were sensitive to oxacillin (114/114, 100.0%), linezolid (94/94, 100.0%), vancomycin (114/114, 100.0%), and tigecycline (84/84, 100.0%); it's resistance rates to penicillin G, erythromycin and clindamycin were 78.1% (89/114), 59.7% (68/114) and 46.5% (53/114), respectively. The drug resistance rate of MSSA to penicillin G, erythromycin and clindamycin were lower than those of MRSA (χ²=11.71,19.74,23.95, respectively, all P<0.001). Conclusions: The age of consultation for pediatric infectious vulvovaginitis is mainly around 6 years. The most common pathogens are S.pyogenes, H.influenzae and Escherichia coli. Third generation cephalosporins can be used as the first choice of empirical anti-infection drugs. However, the results of drug susceptibility should be considered for targeted treatment.
Female
;
Adolescent
;
Child
;
Humans
;
Anti-Bacterial Agents/therapeutic use*
;
Vancomycin/therapeutic use*
;
Methicillin-Resistant Staphylococcus aureus
;
Clindamycin/therapeutic use*
;
Ceftriaxone/therapeutic use*
;
Tigecycline/therapeutic use*
;
Linezolid/therapeutic use*
;
Levofloxacin/therapeutic use*
;
Retrospective Studies
;
Microbial Sensitivity Tests
;
Staphylococcus aureus
;
Staphylococcal Infections/drug therapy*
;
Erythromycin/therapeutic use*
;
Methicillin
;
Penicillin G/therapeutic use*
;
Escherichia coli
;
Drug Resistance, Bacterial
3.Aripiprazole in the treatment of acute episode of schizophrenia: a real-world study in China.
Qian LI ; Yun'ai SU ; Xuemei LIAO ; Maosheng FANG ; Jianliang GAO ; Jia XU ; Mingjun DUAN ; Haiying YU ; Yang YANG ; Zhiyu CHEN ; Jintong LIU ; Shaoxiao YAN ; Peifen YAO ; Shuying LI ; Changhong WANG ; Bin WU ; Congpei ZHANG ; Tianmei SI
Chinese Medical Journal 2023;136(9):1126-1128
4.Evaluation of Microsphere-based xMAP Test for gyrA Mutation Identification in Mycobacterium Tuberculosis.
Xi Chao OU ; Bing ZHAO ; Ze Xuan SONG ; Shao Jun PEI ; Sheng Fen WANG ; Wen Cong HE ; Chun Fa LIU ; Dong Xin LIU ; Rui Da XING ; Hui XIA ; Yan Lin ZHAO
Biomedical and Environmental Sciences 2023;36(4):384-387
5.Distribution and Drug Resistance of Pathogens in Oral Mucositis Associated with Chemotherapy in Patients with Malignant Hematopathy.
Jin QIU ; Zi-Hao ZHANG ; Xiao-Ting LIU ; Cheng-Long LIU ; Si-Yi ZHU ; Zhao-Qu WEN
Journal of Experimental Hematology 2023;31(1):274-279
OBJECTIVE:
To analyze the distribution and drug resistance of pathogens in oral mucositis associated with chemotherapy in hospitalized patients with malignant hematopathy, so as to provide scientific evidences for rational selection of antibiotics and infection prevention and control.
METHODS:
From July 2020 to June 2022, 167 patients with malignant hematopathy were treated with chemical drugs in the Department of Hematology, Hainan Hospital, and secretions from oral mucosal infected wounds were collected. VITEK2 COMPECT automatic microbial identification system (BioMerieux, France) and bacterial susceptibility card (BioMerieux) were used for bacterial identification and drug susceptibility tests.
RESULTS:
A total of 352 strains of pathogens were isolated from 167 patients, among which 220 strains of Gram-positive bacteria, 118 strains of Gram-negative bacteria and 14 strains of fungi, accounted for 62.50%, 33.52% and 3.98%, respectively. The Gram-positive bacteria was mainly Staphylococcus and Streptococcus, while Gram-negative bacteria was mainly Klebsiella and Proteus. The resistance of main Gram-positive bacteria to vancomycin, ciprofloxacin and gentamicin was low, and the resistance to penicillin, cefuroxime, ampicillin, cefotaxime, erythromycin and levofloxacin was high. The main Gram-negative bacteria had low resistance to gentamicin, imipenem and penicillin, but high resistance to levofloxacin, cefotaxime, cefuroxime, ampicillin and vancomycin. The clinical data of oral mucositis patients with oral ulcer (severe) and without oral ulcer (mild) were compared, and it was found that there were statistically significant differences in poor oral hygiene, diabetes, sleep duration less than 8 hours per night between two groups (P<0.05).
CONCLUSION
Gram-positive bacteria is the main pathogen of oral mucositis in patients with malignant hematopathy after chemotherapy. It is sensitive to glycopeptide antibiotics and aminoglycosides antibiotics. Poor oral hygiene, diabetes and sleep duration less than 8 hours per night are risk factors for oral mucositis with oral ulcer (severe).
Humans
;
Vancomycin/therapeutic use*
;
Cefuroxime
;
Levofloxacin
;
Oral Ulcer/drug therapy*
;
Drug Resistance, Bacterial
;
Anti-Bacterial Agents/adverse effects*
;
Ampicillin
;
Penicillins
;
Cefotaxime
;
Gram-Positive Bacteria
;
Gram-Negative Bacteria
;
Gentamicins
;
Stomatitis/drug therapy*
6.Levofloxacin combined with cellulase can eradicate bacille Calmette-Guerin biofilm infection.
Zhi Fei ZHANG ; Hong Jian LIAO ; Min YANG ; Can HU ; Yong Hong DU
Journal of Southern Medical University 2023;43(2):257-264
OBJECTIVE:
To investigate the inhibitory effects of levofloxacin (LEV) combined with cellulase against bacille CalmetteGuerin (BCG) biofilms in vitro.
METHODS:
The mature growth cycle of BCG biofilms was determined using the XTT method and crystal violet staining. BCG planktonic bacteria and BCG biofilms were treated with different concentrations of LEV and cellulose alone or jointly, and the changes in biofilm biomass were quantified with crystal violet staining. The mature BCG biofilm was then treated with cellulase alone for 24 h, and after staining with SYTO 9 and Calcofluor White Stain, the number of viable bacteria and the change in cellulose content in the biofilm were observed with confocal laser scanning microscopy. The structural changes of the treated biofilm were observed under scanning electron microscopy.
RESULTS:
The MIC, MBC and MBEC values of LEV determined by broth microdilution method were 4 μg/mL, 8 μg/mL and 1024 μg/mL, respectively. The combined treatment with 1/4×MIC LEV and 2.56, 5.12 or 10.24 U/mL cellulase resulted in a significant reduction in biofilm biomass (P < 0.001). Cellulase treatments at the concentrations of 10.24, 5.12 and 2.56 U/mL all produced significant dispersion effects on mature BCG biofilms (P < 0.001).
CONCLUSION
LEV combined with cellulose can effectively eradicate BCG biofilm infections, suggesting the potential of glycoside hydrolase therapy for improving the efficacy of antibiotics against biofilmassociated infections caused by Mycobacterium tuberculosis.
Levofloxacin/pharmacology*
;
Gentian Violet/pharmacology*
;
BCG Vaccine/pharmacology*
;
Anti-Bacterial Agents/pharmacology*
;
Biofilms
;
Cellulases/pharmacology*
;
Microbial Sensitivity Tests
7.Molecular Detection of Ofloxacin and Kanamycin Resistance in Patients with MDR and Non-MDR TB from Suburban Districts in Hangzhou, China, 2019-2020.
Qing Jun JIA ; Mei Chun ZENG ; Li XIE ; Qing Lin CHENG ; Yin Yan HUANG ; Qing Chun LI ; Yi Fei WU ; Li Yun AI ; Min LU ; Zi Jian FANG
Biomedical and Environmental Sciences 2022;35(5):468-471
Antitubercular Agents/therapeutic use*
;
China/epidemiology*
;
Drug Resistance, Multiple, Bacterial
;
Extensively Drug-Resistant Tuberculosis
;
Humans
;
Kanamycin Resistance
;
Microbial Sensitivity Tests
;
Mycobacterium tuberculosis
;
Ofloxacin/pharmacology*
;
Tuberculosis, Multidrug-Resistant/epidemiology*
8.Postoperative safety outcomes in patients undergoing routine Phacoemulsification Cataract Surgery with Intraoperative Intracameral Injection of Preservative-Free Moxifloxacin versus Levofloxacin
Franz Marie Cruz ; Harvey S. Uy ; Carlo Josemaria Rubio ; Pik Sha Chan
Philippine Journal of Ophthalmology 2022;47(1):15-22
Purpose:
This study compared the safety outcomes of two intracameral fluoroquinolone antibiotics,
moxifloxacin and levofloxacin, as prophylaxis treatment in eyes that underwent uncomplicated cataract surgery.
Methods:
This is a prospective, double-masked, randomized, interventional, single-center clinical trial. Eyes
with visually-significant cataracts underwent phacoemulsification and received preservative-free intracameral
0.5% moxifloxacin [58 eyes (M group)] or 0.5% levofloxacin [56 eyes (L group)] at the end of the surgery as
antibiotic prophylaxis. The following safety parameters were evaluated postoperatively at Day 1, Week 1 and
Month 1: central retinal thickness (CRT), macular volume (MV), central corneal thickness (CCT), and
endothelial cell density (ECD). In-between group comparison was made at each of the 4 study visits using
Student’s t-test.
Results:
Both M and L groups had similar baseline characteristics. There were no significant differences in
CRT, MV, CCT and ECD between the 2 groups at each time point in the study. There were no significant
differences in the mean changes in CRT, MV, CCT and ECD from baseline to final visit between the 2 groups.
No study-related adverse events were observed during the study period.
Conclusion
Intracameral application of preservative-free 0.5% moxifloxacin and 0.5% levofloxacin appear to
have similar safety outcomes when used as antibacterial prophylaxis among eyes undergoing cataract surgery.
Based on the results, both fluoroquinolone agents are potentially suitable options for endophthalmitis
chemoprophylaxis.
Levofloxacin
;
Moxifloxacin
;
Fluoroquinolones
9.Evaluation of the efficiency of ciprofloxacin against S. Typhi by altering the production of cytokines in acute typhoid fever in patients at Al-Diwaniyah Hospitals, Iraq
Baleegh A Kadhim ; Zeayd Fadhil Saeed ; Sura A Al-Ganahi
Malaysian Journal of Microbiology 2022;18(5):562-570
Aims:
Typhoid fever is a life-threatening disease in the developing world that claims >600,000 deaths per year. Its causative agent Salmonella Typhimurium (S. Typhi) can be treated with ciprofloxacin, an effective broad-spectrum antibiotic that enhances the natural host defenses. However, the emergence of resistant bacterial strains may be a warning alarm against the clinical use of this antibiotic. This study was aimed to investigate the efficiency of ciprofloxacin treatment (250 mg/mL) against S. Typhi by altering the production of serum cytokines IL-10, 1L-6 and TNF-α in acute typhoid fever patients in Diwanyah Hospitals.
Methodology and results:
ELISA and Western Blot methods were used to investigate cytokine levels in patients and healthy controls sera. Our results showed that all cytokines’ levels before treatment with ciprofloxacin were significantly higher than the control (healthy group). However, treated patients with ciprofloxacin revealed a significantly reduced concentration of IL-10 and TNF-α compared to untreated control samples. However, the level of IL-6 was higher even with ciprofloxacin treatment.
Conclusion, significance and impact of study
The study concluded that ciprofloxacin (250 mg/mL) might significantly alter serum cytokines IL-6, IL-10 and TNF-α levels in acute typhoid fever patients. Therefore, further molecular studies are essential to understand the effect of ciprofloxacin on the production of cytokines.
Typhoid Fever
;
Ciprofloxacin
;
Salmonella typhimurium
;
Cytokines
10.The combination of ciprofloxacin and indomethacin suppresses the level of inflammatory cytokines secreted by macrophages in vitro.
Ke LIU ; Jing YU ; Yu XIA ; Lei-Ting ZHANG ; Sui-Yan LI ; Jun YAN
Chinese Journal of Traumatology 2022;25(6):379-388
PURPOSE:
The combined use of antibiotics and anti-inflammatory medicine to manage bacterial endotoxin-induced inflammation following injuries or diseases is increasing. The cytokine level produced by macrophages plays an important role in this treatment course. Ciprofloxacin and indomethacin, two typical representatives of antibiotics and anti-inflammatory medicine, are cost-effective and has been reported to show satisfactory effect. The current study aims to investigate the effect of ciprofloxacin along with indomethacin on the secretion of inflammatory cytokines by macrophages in vitro.
METHODS:
Primary murine peritoneal macrophages and RAW 264.7 cells were administrated with lipopolysaccharide (LPS) for 24 h. The related optimal dose and time point of ciprofloxacin or indomethacin in response to macrophage inflammatory response inflammation were determined via macrophage secretion induced by LPS. Then, the effects of ciprofloxacin and indomethacin on the secretory functions and viability of various macrophages were determined by enzyme-linked immunosorbent assay and flow cytometry analysis, especially for the levels of interleukin (IL)-1β, IL-6, IL-10, and tumor necrosis factor (TNF)-α. The optimal dose and time course of ciprofloxacin affecting macrophage inflammatory response were determined by testing the maximum inhibitory effect of the drugs on pro-inflammatory factors at each concentration or time point.
RESULTS:
According to the levels of cytokines secreted by various macrophages (1.2 × 106 cells/well) after administration of 1 μg/mL LPS, the optimal dose and usage timing for ciprofloxacin alone were 80 μg/mL and 24 h, respectively, and the optimal dose for indomethacin alone was 10 μg/mL. Compared with the LPS-stimulated group, the combination of ciprofloxacin and indomethacin reduced the levels of IL-1β (p < 0.05), IL-6 (p < 0.05), IL-10 (p < 0.01)), and TNF-α (p < 0.01). Furthermore, there was greater stability in the reduction of inflammatory factor levels in the combination group compared with those in which only ciprofloxacin or indomethacin was used.
CONCLUSION
The combination of ciprofloxacin and indomethacin suppressed the levels of inflammatory cytokines secreted by macrophages in vitro. This study illustrates the regulatory mechanism of drug combinations on innate immune cells that cause inflammatory reactions. In addition, it provides a new potential antibacterial and anti-inflammatory treatment pattern to prevent and cure various complications in the future.
Humans
;
Mice
;
Animals
;
Cytokines
;
Lipopolysaccharides/pharmacology*
;
Interleukin-10
;
Indomethacin/therapeutic use*
;
Interleukin-6/therapeutic use*
;
Ciprofloxacin/therapeutic use*
;
Macrophages
;
Tumor Necrosis Factor-alpha
;
Inflammation/drug therapy*
;
Anti-Inflammatory Agents/therapeutic use*
;
Anti-Bacterial Agents/therapeutic use*


Result Analysis
Print
Save
E-mail